Bone drugs may raise risk of throat cancer

Posted In: Life Sciences

By MARIA CHENG - AP Medical Writer - Associated Press

Thursday, September 2, 2010


newsvine diigo google
slashdot
Share
Loading...

People who take many bone-strengthening drugs for several years may have a slightly higher risk of esophageal cancer, a new study says.

British researchers analyzed the records of nearly 3,000 people with esophageal cancer and compared each case to five other similar people who didn't have the disease. Researchers also looked at about 10,000 people with bowel cancer and about 2,000 people with stomach cancer. In total, the study included more than 90,000 people. They followed them for about 8 years.

The paper was only observational and did not show the osteoporosis drugs caused cancer. Previous studies have been divided over whether the risk is real. Last month, a paper was published in the Journal of the American Medical Association that examined about 80,000 people. It found the drugs were not connected to esophageal or stomach cancer.

Osteoporosis drugs are commonly prescribed to post-menopausal women and their use in the West has soared in recent years.

Normally, the risk of developing cancer of the esophagus, or throat, in people aged 60 to 79 is 1 in 1,000. In people who had 10 or more prescriptions for drugs to prevent osteoporosis for about 5 years, the risk was 2 in 1,000. Researchers did not find any link between the drugs and stomach or bowel cancer. The study was paid for by Britain's Medical Research Council and Cancer Research UK. It was published Friday in the medical journal, BMJ.

"Esophageal cancer is an uncommon cancer," said Jane Green, a clinical epidemiologist at the University of Oxford, one of the paper's authors. "Even a doubled risk is still a very small risk." The chances of developing esophageal cancer after taking the bone-building drugs, known as bisphosphonates, are much smaller than known causes like being obese, smoking or drinking.

But the disease is often caught late, as it was in actor Michael Douglas, which lowers the survival rate.

Green said the findings shouldn't affect patients taking osteoporosis drugs, but added the medicines should be watched closely. "People are increasingly being prescribed bisphosphonates and we just don't know enough about their use over the long term," she said. The pills have other side effects including throat ulcers, abdominal pain and an irregular heartbeat.

Experts aren't sure why the drugs might lead to throat cancer, but the pills can cause inflammation in the esophagus, which could make cancer more likely.

In the U.S., the Food and Drug Administration has received reports of a few dozen people getting esophageal cancer after taking osteoporosis pills, but there is no proof the drugs caused the cancers.

"The possibility of adverse effects on the esophagus should prompt doctors who prescribe these drugs to consider risks versus benefits," wrote Diane K. Wysowski, an epidemiologist at the FDA, in an accompanying commentary.

Wysowski said patients should take the medicines carefully, like with a full glass of water before eating and not reclining for at least 30 minutes afterward.

"Doctors should tell patients to report difficulty in swallowing and throat, chest or digestive discomfort so that they can be promptly evaluated and possibly advised to discontinue the drug," she wrote.

____

Online:

www.bmj.com

www.cancerresearchuk.org

0 Comments

blog comments powered by Disqus

New To Market

more

JEOL to launch world's smallest solid-state NMR probe
JEOL to launch world's smallest solid-state NMR probe

According to JEOL Resonance, a new benchmark for resolution and benchmark will be set with its introduction next week of a new 0.75-mm solid state nuclear magnetic resonance (NMR) probe. The probe is capable of high resolution sample analysis by spinning the sample at 110 kHz, the world's fastest spinning speed for NMR.

Energy Harvesting Subsystems for Wireless Sensors

Nextreme Thermal Solutions has developed two new energy harvesting subsystems for the plumbing and HVAC industries. The subsystems are the latest additions to Nextreme's Thermobility energy harvesting platform that uses thin-film thermoelectric technology to convert available thermal energy into electric power for a variety of autonomous self-powered applications.

Tools & Technology

more

Microscope System with LED Illumination
Microscope System with LED Illumination

Leica Microsystems has introduced the Leica DM4000 B LED, a microscope system with LED illumination suited for biomedical applications.

Liquid Handler

Gilson Inc. has introduced the GX-241 liquid handler, a compact liquid handler suited for application and laboratories where bench space is at a premium.

Advertisement

Advertisement

Top Stories and Headlines
EVERY DAY!

FREE Email Newsletter